Evidence map›Paper›PMID 34084980›Full record

ArticleKidney cancer (Clifton, Va.)2020

Prognostic Value of Histologic Subtype and Treatment Modality for T1a Kidney Cancers.

Michael Siev, Audrey Renson, Hung-Jui Tan, Tracy L Rose, Stella K Kang, William C Huang, Marc A Bjurlin

Open access · diamondAbstract read
In one paragraph

Article in Kidney cancer (Clifton, Va.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Michael SievDepartment of Urology, Division of Urologic Oncology, NYU Langone Health, New York, NY, USA.
Audrey RensonDepartment of Clinical Research, NYU Langone Hospital - Brooklyn, Brooklyn, NY, USA.
Hung-Jui TanDepartment of Urology, Lineberger Comprehensive Cancer Center, Multidisciplinary Genitourinary Oncology, University of North Carolina, Chapel Hill, NC, USA.
Tracy L RoseDepartment of Hematology/Oncology, Lineberger Comprehensive Cancer Center, Multidisciplinary Genitourinary Oncology, University of North Carolina, Chapel Hill, NC, USA.
Stella K KangDepartment of Radiology, NYU Langone Health, New York, NY, USA.
William C HuangDepartment of Urology, Division of Urologic Oncology, NYU Langone Health, New York, NY, USA.
Marc A BjurlinDepartment of Urology, Lineberger Comprehensive Cancer Center, Multidisciplinary Genitourinary Oncology, University of North Carolina, Chapel Hill, NC, USA.
NYU Langone Health · USUniversity of North Carolina at Chapel Hill · USBrooklyn Hospital Center · US

Funding

Selective histone deacetylase inhibition with entinostat to enhance the anti-tumor immune response to immune checkpoint inhibition in urothelial cancerK08CA248967 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROSE, TRACY L · 2020 to 2022
$787k
NCI NIH HHS K08 CA248967
6 · The paper itself

Abstract

introductionTo evaluate overall survival (OS) of T1a kidney cancers stratified by histologic subtype and curative treatment including partial nephrectomy (PN), percutaneous ablation (PA), and radical nephrectomy (RN). MATERIALS AND

methodsWe queried the National Cancer Data Base (2004-2015) for patients with T1a kidney cancers who were treated surgically. OS was estimated by Kaplan-Meier curves based on histologic subtype and management. Cox proportional regression models were used to determine whether histologic subtypes and management procedure predicted OS.

results46,014 T1a kidney cancers met inclusion criteria. Kaplan Meier curves demonstrated differences in OS by treatment for clear cell, papillary, chromophobe, and cystic histologic subtypes (all

conclusionsIn patients with pathologic T1a RCC, patterns of OS differed by surgery and histologic subtype. Patients receiving PN appears to have better prognosis than both PA and RN. However, the incorporation of histologic subtype and treatment modality into a risk stratification model to predict OS had limited utility compared with variables representing competing risks.

Indexed as

histologic subtypeoverall survivalpartial nephrectomypercutaneous ablationradical nephrectomyRenal cell carcinomaT1a

Identifiers

PMID34084980
PMCPMC8171275
OpenAlexW3011190655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.